secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEOGENOMICS INC (NEO)
CIK:        0001077183
Form:       8-K
Filed at:   2026-10-05T20:08:15+00:00
Accession:  0001077183-26-000069
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 5.02, 5.03, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

NeoGenomics names Warren Stone CEO effective Jan 4, 2027; Zook to Executive Chair; Q3 revenue ~$209M
--------------------------------------------------------------------------------

- Warren Stone, President & COO since April 2025, becomes CEO and board member effective January 4, 2027; Tony Zook moves from CEO to Executive Chairman the same day.
- Stone's employment agreement: $850,000 base salary, 100% target bonus, and annual equity awards with aggregate target value ~$8,000,000 beginning FY2027.
- Zook's amended agreement: $400,000 base salary, 50% target bonus, and annual restricted stock unit awards with target value ~$3,000,000.
- Board Chair Lynn Tetrault steps down January 4, 2027, remains an independent director until the 2027 annual meeting and won't stand for reelection; Michael Kelly becomes Lead Independent Director.
- Preliminary Q3 2026 revenue ~$209M with NGS revenue up ~28% YoY; FY revenue and adjusted EBITDA guidance reiterated from July 28, 2026, with midpoint revenue expected to rise.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1077183/000107718326000069/0001077183-26-000069-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1077183/000107718326000069/neo-20261005.htm
  HTML page:      https://secwatch.observer/filing/0001077183-26-000069

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer